Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComBET
NCT05327010Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZEN3694, talazoparib in solid tumor, sponsored by National Cancer Institute. Started Nov 2022; status: active, not recruiting.
02
Drugs
ZEN3694talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05327010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327010.